RxDoctor Payments DataLook up a doctor →

Peter Emanuel, MD

Hematology & Oncology · Little Rock, ARNPI 1205844594

Payments from drug & device makers

$52,770in general payments, 2019–2025

Across 1,080 payments — averaging $48.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$30K
  • Janssen Scientific Affairs, LLC$3K
  • AstraZeneca$3K
  • Novartis$1K
  • Merck$1K
  • Adaptive Biotechnologies Corporation$1K
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bristol Myers Squibb122$30,012
Janssen Scientific Affairs, LLC3$2,900
AstraZeneca(2 entities)64$2,642
Novartis96$1,484
Merck66$1,178
Adaptive Biotechnologies Corporation3$1,050
Johnson & Johnson(2 entities)47$972
Pfizer57$839
Incyte Corporation45$803
Lilly USA, LLC25$608
Seagen Inc.37$598
Beigene USA, Inc.24$549
Exelixis Inc.29$504
Genentech USA, Inc.38$501
Sanofi22$471
E.r. Squibb & Sons, L.L.C.25$458
AbbVie23$451
Amgen29$446
Astellas Pharma US Inc22$423
Daiichi Sankyo Inc.20$376
EMD Serono, Inc.19$373
Gilead(2 entities)19$345
Alnylam Pharmaceuticals Inc.19$344
Eisai Inc.15$317
Pharmacyclics LLC, An Abbvie Company17$314
Ipsen Biopharmaceuticals, Inc14$259
Regeneron Healthcare Solutions, Inc.11$233
AVEO Pharmaceuticals, Inc.10$205
Pharmaessentia USA Corporation10$202
Array Biopharma Inc15$189
Sobi, Inc8$177
Bayer9$166
GSK9$163
Pharmacosmos Therapeutics Inc.9$143
Karyopharm Therapeutics Inc.9$137
Puma Biotechnology, Inc.7$135
Rigel Pharmaceuticals, Inc.8$133
Geron Corporation1$124
Servier Pharmaceuticals LLC6$113
Takeda Pharmaceuticals U.S.A., Inc.5$106
Boehringer Ingelheim4$97
Kyowa Kirin, Inc.3$95
Epizyme, Inc.6$88
Sanofi-aventis U.S. LLC1$86
Genentech, Inc.1$83
ADC Therapeutics America, Inc.4$72
Morphosys, US Inc.3$70
Mirati Therapeutics, Inc.4$67
Recordati_rare_diseases_inc.3$64
G1 Therapeutics, Inc.4$58
Beone Medicines USA, Inc.3$58
AMAG Pharmaceuticals, Inc.3$53
Viiv Healthcare Company3$51
Blueprint Medicines Corporation2$43
Stemline Therapeutics Inc.3$42
Agios Pharmaceuticals, Inc.3$41
Acceleron Pharma, Inc.2$35
Intercept Pharmaceuticals, Inc.1$28
Fresenius Kabi USA, LLC1$27
Abbott1$25

How this compares

$52,770 in reported general payments places this provider in the 70th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$97,546
Medicare patients
240
Services billed
3,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Little Rock

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →